Kavigale (Sipavibart)

Sipavibart is currently under clinical investigation and does not have approved therapeutic indications.

• No approved indication: currently not authorized for clinical use.
• Research use – infectious disease: being studied for potential antiviral activity.
• Research use – inflammatory disorders: evaluated for modulation of inflammatory pathways.
• Research use – oncology: explored as a candidate in early‑phase cancer trials.

• The exact mechanism of Sipavibart has not been fully disclosed. Preclinical studies indicate that the compound interacts with cellular signaling pathways that modulate immune responses, potentially affecting cytokine production and receptor activation, though detailed pharmacodynamic data remain limited.

Adverse reactions reported in early clinical studies are limited and primarily related to the route of administration.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema and edema.
• Fever: transient low‑grade temperature rise.
• Headache: mild to moderate intensity.
• Nausea: occasional mild gastrointestinal upset.
• Fatigue: transient feeling of tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: sudden drop in blood pressure post‑administration.
• Thrombocytopenia: marked reduction in platelet count.
• Hepatic enzyme elevation: significant increase in liver function tests.
• Immune‑mediated reactions: such as serum sickness.
• Multi‑organ dysfunction: rare cases of systemic involvement.

When handling Sipavibart, clinicians should observe standard safety measures and consider patient‑specific factors.

• Patient assessment: evaluate allergy history before administration.
• Monitoring: observe vital signs during and after injection.
• Contraindications: avoid in patients with known hypersensitivity to Sipavibart.
• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion; consider potential risk to the infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potential drug interactions for Sipavibart are not fully characterized; caution is advised with agents that affect immune function or hemostasis.

Major Interactions (Avoid)

• Live vaccines: may reduce vaccine efficacy.
• Immunosuppressants: possible additive immunomodulation.
• Anticoagulants: increased risk of bleeding.

Moderate Interactions (Monitor Closely)

• CYP450 substrates: potential metabolic interaction; monitor levels.
• Antihistamines: may mask early allergic signs.
• NSAIDs: could enhance renal adverse effects.